Castelfranco Veneto
Castelfranco Veneto
Castelfranco Veneto, Italy19 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Active, not recruiting | Not stated | 2026-09-30 | NCT04579367 | |
| A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05714202 | |
| Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study" | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Not stated | 2026-09-09 | NCT07746232 | |
| Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors | Haemophilia A With Inhibitors; Haemophilia B With Inhibitors | Active, not recruiting | Phase 3 | 2026-09-09 | NCT04083781 | |
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-09-08 | NCT05929222 | |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-08-18 | NCT06792695 | |
| IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, disease, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2026-08-14 | NCT06713837 | |
| Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract cancer, biliary tract disorder, neoplasm | Active, not recruiting | Phase 3 | 2026-07-29 | NCT05771480 | |
| Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) | Bladder Carcinoma in Situ (CIS) | Active, not recruiting | Phase 3 | 2026-06-23 | NCT05024773 | |
| Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm | Recruiting | Phase 3 | 2026-06-15 | NCT06006117 | |
| Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Not stated | 2026-06-02 | NCT03695978 | |
| Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Not applicable | 2026-03-06 | NCT04460963 | |
| Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Not stated | 2025-12-29 | NCT06588205 | |
| A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Not stated | 2025-12-29 | NCT06008691 | |
| SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project | Atrophy, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Sarcopenia, Signs and Symptoms, muscular atrophy, nervous system disorder | Recruiting | Not stated | 2025-12-08 | NCT06156774 | |
| Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) | High-risk MDS | Recruiting | Phase 3 | 2025-04-29 | NCT04184505 | |
| Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2024-11-08 | NCT04763928 | |
| Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2024-11-08 | NCT04168502 | |
| Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2022-08-26 | NCT04442412 |